Market
BSE Prices delayed by 5 minutes... << Prices as on Jun 13, 2025 >>  ABB India  5996.85 [ -0.59% ] ACC  1847.35 [ -1.00% ] Ambuja Cements  543.25 [ -0.92% ] Asian Paints Ltd.  2215.3 [ -0.12% ] Axis Bank Ltd.  1205.95 [ -0.56% ] Bajaj Auto  8463.8 [ -1.20% ] Bank of Baroda  239.1 [ -0.83% ] Bharti Airtel  1842.15 [ -0.10% ] Bharat Heavy Ele  253.55 [ -0.14% ] Bharat Petroleum  312.65 [ -1.90% ] Britannia Ind.  5569.45 [ -0.01% ] Cipla  1505.4 [ 0.22% ] Coal India  391.35 [ -0.32% ] Colgate Palm.  2373.75 [ -1.26% ] Dabur India  466.65 [ -1.31% ] DLF Ltd.  851.8 [ 0.48% ] Dr. Reddy's Labs  1361.45 [ -0.12% ] GAIL (India)  191.4 [ -0.42% ] Grasim Inds.  2664.95 [ -0.87% ] HCL Technologies  1694.85 [ -0.43% ] HDFC Bank  1917.25 [ -1.27% ] Hero MotoCorp  4330.55 [ -0.70% ] Hindustan Unilever L  2319.1 [ -0.65% ] Hindalco Indus.  641.55 [ -1.45% ] ICICI Bank  1416.2 [ -0.64% ] Indian Hotels Co  733.25 [ -1.46% ] IndusInd Bank  816.55 [ -1.59% ] Infosys L  1601.55 [ -0.36% ] ITC Ltd.  413.9 [ -1.67% ] Jindal St & Pwr  920.7 [ -1.99% ] Kotak Mahindra Bank  2110.8 [ -0.71% ] L&T  3588.25 [ -0.43% ] Lupin Ltd.  2000.35 [ -1.08% ] Mahi. & Mahi  3006 [ -0.39% ] Maruti Suzuki India  12411.45 [ 0.24% ] MTNL  52.08 [ -4.32% ] Nestle India  2376.5 [ -0.45% ] NIIT Ltd.  134.1 [ -1.58% ] NMDC Ltd.  70.38 [ -2.80% ] NTPC  332 [ -0.43% ] ONGC  251.4 [ 1.45% ] Punj. NationlBak  106.55 [ -1.39% ] Power Grid Corpo  285.7 [ -1.07% ] Reliance Inds.  1427.65 [ -0.83% ] SBI  792.4 [ -1.64% ] Vedanta  457.8 [ -0.51% ] Shipping Corpn.  226.5 [ 9.74% ] Sun Pharma.  1688.7 [ 0.10% ] Tata Chemicals  925.2 [ -0.77% ] Tata Consumer Produc  1078.45 [ -0.52% ] Tata Motors  712.05 [ -0.41% ] Tata Steel  152.2 [ -0.43% ] Tata Power Co.  397.35 [ -1.06% ] Tata Consultancy  3447.1 [ 0.38% ] Tech Mahindra  1658.95 [ 0.93% ] UltraTech Cement  11220.7 [ -0.83% ] United Spirits  1452.15 [ -2.22% ] Wipro  260.2 [ 0.29% ] Zee Entertainment En  137.35 [ 2.08% ] 
Krishna Institute of Medical Sciences Ltd. Notes to Accounts
Search Company 
You can view the entire text of Notes to accounts of the company for the latest year
Market Cap. (Rs.) 27207.45 Cr. P/BV 13.59 Book Value (Rs.) 50.03
52 Week High/Low (Rs.) 708/394 FV/ML 2/1 P/E(X) 70.76
Bookclosure 13/09/2024 EPS (Rs.) 9.61 Div Yield (%) 0.00
Year End :2024-03 

(ii) Rights, preferences and restrictions attached to equity shares of Rs. 10 each, fully paid up:

The Company has only one class of equity shares having par value of Rs. 10/- each. Each equity share holder is entitled to one vote per equity share held. In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

1. Securities premium

Securities premium is used to record the premium received on issue of shares.

2. Adjustment reserve

During the year ended 31 March 2014, the Company had a share swap with the shareholders of Bollineni Heart Centre Limited (“transferor Company”) and the differential of Rs. 41.49 was added to the Adjustment reserve. In the same year, the Company allotted shares to Bollineni Ramanaiah Memorial Hospitals Private Limited (“Demerged Company”) and the difference between the consideration payable and the value of net assets taken over amounting to Rs. 16.15 was added to the Adjustment reserve.

3. Retained earnings

Retained earnings are the profits/losses (net of appropriations) of the Company earned till date, including items of other comprehensive income.

i Axis Bank - Term loan Facility-1 is secured by way of exclusive charge on entire fixed assets of the Thane project ,both movebale and immovable (including lease hold right) present and future. The loan is repayable in 120 structured monthly instalments after 12 months from estimated date of completion of 31 March 2025 and carries an interest rate of Repo rate 2.20% per annum (31 March 2023: Nil per annum), currently the interest rate is 8.45% p.a (31 March 2023 : Nil)

ii Axis Bank - Term loan Facility-2 is secured by way of first pari pasu charge on entire fixed assets of the Company (both movebale and immovable) pertaining to Secunderabad hospital along with mortgage on lease hold rights of the hospital lands pertaining to Secunderabad hospital which are not owned by the Company. The loan is repayable in 72 equated monthly instalments post moratorium period of 12 months from the date of first disbursment and carries an interest rate of Repo rate 2.15% per annum (31 March 2023: Nil per annum), currently the interest rate is 8.65% p.a (31 March 2023 : Nil)

iii Bank Overdraft is secured by first pari pasu charge on current assets of the Company and repayable on demand and carries an interest rate of 8.25% per annum linked to 3 months MCLR (31 March 2023: Nil per annum).

iv Cash credit is secured by first pari pasu charge on current assets of the Company and repayable on demand and carries an interest rate of 8.75% per annum (31 March 2023: Nil per annum).

v The quarterly returns or statements of the current assets filed by the company with banks or financial institutions are in agreement with the books of accounts.

2.25 Contingent liabilities and commitments (a) Contingent liabilities

Particulars

As at 31 March 2024

As at 31 March 2023

i) Guarantee issued by the Company on behalf of related entities

5,440.00

5,440.00

ii) Good and Service tax matters in dispute

35.21

6.59

iii) Medical and other claimross, excluding interest/costs)

109.69

111.37

iv) The Company has obtained a stay from High Court for the state of Andhra Pradesh, dated 11 November 2014, directing the local authorities not to proceed with the acquisition of part of the building in Nellore for the purpose of road widening. No provision thereof has been made in the Standalone financials statements.

v) An individual has filed a consumer case at National Consumer Disputes Redressal Commission against the Company along with 3 other hospitals demanding a total compensation of Rs. 235.01 (31 March 2023: Rs. 235.01) along with a further interest @ 18% p.a towards medical negligence. Based on the legal opinion obtained by the Company and the internal evaluation by the management, the Company believes that it has strong case in this regard and there shall not be any outflow of resources. No provision thereof has been made in the Standalone financial statement.

vi) On 28 February 2019, the Supreme Court of India issued a judgement which provided further guidance for companies in determining which components of their employee's compensation are subject to statutory withholding obligations, and matching employer contribution obligations, for Provident Fund contributions under Indian law. There are interpretative issues relating to the retrospective applicability of the judgement. However, from the date of order, the Company has complied with the aforesaid Supreme court's judgement. The Company will evaluate the same and update its position for earlier years, if any on receiving further clarity on the subject.

Notes:

i. Pending resolution of the respective proceedings, it is not practicable for the Company to estimate the timings of the cash flow, if any, in respect of the above as it is determinable only on receipt of judgements/decisions pending with various forums/authorities.

ii. The Company has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required and disclosed as contingent liabilities where applicable in its standalone financial statements. The Company does not expect the outcome of these proceeding to have a materially adverse effect on its financial position.

(b) Commitments

Particulars

As at 31 March 2024

As at 31 March 2023

I) Capital commitment

i) Estimated amount of contracts remaining to be executed on capital account and not provided for (net of advances)

1,942.39

2,070.56

2.26 Lease

Operating and Finance leases in the capacity of lessee

The Company has land lease contract used in its operations with lease term of 99 years. The Company’s obligations under its lease is secured by the lessor’s title to the leased assets.

Leases of buildings with lease terms of 12 months or less and leases of office equipment with low value. The Company applies the ‘short-term lease’ and ‘lease of low-value assets’ recognition exemptions for these leases.

The Company has several lease contracts that include extension and termination options. These options are negotiated by management to provide flexibility in managing the leased-asset portfolio and align with the Company’s business needs. Management exercises significant judgement in determining whether these extension and termination options are reasonably certain to be exercised.

2.27 Employee benefits

(i) Defined benefit plan

The Company operate post-employment defined benefit plan that provides for gratuity. The Company accrues gratuity as per the provisions of the payment of Gratuity Act, 1972 as applicable as at the balance sheet date. The gratuity plan entitles an employee, who has rendered at least five years of continuous services, to receive one-half month’s salary for each year of completed services at the time of retirement/exit. The gratuity fund is administered by trust formed for this purpose and is

(!!!) The Code on Social Security, 2020 (‘Code’) relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company is assessing the impact of the Code and will record any related impact in the period of the Code becomes effective.

Terms and conditions:

All transactions with these related parties are priced on an arm's length basis and resulting outstanding receivables and payables including financial assets and financial liabilities balances are settled in cash within a range of 30-120 days of the transaction date. None of the balances are secured.

2.30 Segment information

The Managing Director of the Company takes decision in respect of allocation of resources and assesses the performance basis the report/ information provided by functional heads and are thus considered to be Chief Operating Decision Maker.

Based on the Company's business model, medical and healthcare services have been considered as a single business segment for the purpose of making decision on allocation of resources and assessing its performance. Accordingly, there are no separate reportable segments in accordance with the requirements of Ind AS 108 ‘Operating segment’ and hence, there are no additional disclosures to be provided other than those already provided in the Standalone Financials Statements. Presently, the Company’s operations are predominantly confined in India. There are no individual customer contributing more than 10% of Company's total revenue. All non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets of the Company are located in India.

2.31 Due to Micro and Small Enterprises

The Ministry of Micro, Small and Medium Enterprises has issued an office memorandum dated 26 August 2008 which recommends that the Micro and Small Enterprises should mention in their correspondence with its customers the Entrepreneurs Memorandum Number as allocated after filing of the Memorandum. Accordingly, the disclosure in respect of the amount payable to such enterprises as at 31 March 2024 has been made in the standalone financial statements based on information received and available with the Company. Further in view of the Management, the impact of interest, if any, that may be payable in accordance with the provisions of the Micro, Small and Medium Enterprises Development Act, 2006 ("The MSMED Act') is not expected to be material. The Company has not received any claim for interest from any supplier.

2.34 Capital management

The Company’s policy is to maintain a stable capital base so as to maintain investor and creditor confidence and to sustain future development of the business. Management monitors capital on the basis of return on capital employed as well as the ' net debt' to 'total equity' ratio.

* For this purpose, net debt is defined as total borrowings, less cash and cash equivalents. Total equity comprises all components of equity excluding adjustment reserve.

No changes were made in the objectives, policies or processes for managing capital during and for year ended 31 March 2024 and 31 March 2023.

In order to achieve this overall objective, the Company’s capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings that define capital structure requirements. Breaches in meeting the financial covenants would permit the bank to immediately call loans and borrowings. There have been no breaches in the financial covenants of any interest-bearing loans and borrowing during the current and previous year.

The carrying amounts of trade receivables, trade payables, other financials assets, other financial liabilities, current borrowings and cash and cash equivalents and bank balances other than cash and cash equivalents are considered to be the same as their fair values, due to their short-term nature.

The fair values for loans were calculated based on cash flows discounted using a current lending rate. They are classified as level 3 fair values in the fair value hierarchy due to the inclusion of unobservable inputs including counterparty credit risk.

The fair values of long term borrowings are based on discounted cash flows using a current borrowing rate. They are classified as level 3 fair value hierarchy due to the use of unobservable inputs including own credit risk.

The fair values of Investment in mutual funds are based on the market value using net asset value.

B. Financial risk management

The Company’s activities expose it to a variety of financial risks: credit risk, market risk and liquidity risk.

(i) Risk management framework

The Company's Board of Directors have overall responsibility for the establishment and oversight of the Company's risk management framework. The Board of Directors has established the risk management committee, which is responsible for developing and monitoring the Company's risk management policies. The committee reports regularly to the Board of Directors on its activities.

The Company’s risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and Company’s activities. The Company, through its training and management standards and procedures, aims to maintain a disciplined and constructive control environment in which all the employees understand their roles and obligations.

The Company's audit committee oversees how management monitors compliance with the Company's risk management policies and procedures and reviews the adequacy of risk management framework in relation to the risks faced by the

Company. The audit committee is assisted in its oversight role by the internal audit. Internal audit undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the audit committee.

(ii) Credit risk

Credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract, leading to financial loss. The credit risk arises principally from its operating activities (primarily trade receivables and contract assets) and from its investing activities, including deposits with banks and financial institutions and other financial instruments. The carrying amounts of financial assets represent the maximum credit risk exposure.

Credit risk is controlled by analysing credit limits to whom credit has been granted after obtaining necessary approvals for credit. The collection from the trade receivables and contract assets are monitored on a continuous basis by the receivables team.

The Company establishes an allowance for credit loss that represents its estimate of expected losses in respect of trade receivables and contract assets based on the past and the recent collection trend. The maximum exposure to credit risk as at reporting date is primarily from trade receivables and contract assets amounting to Rs. 1,857.21 as on 31 March 2024 (31 March 2023: Rs. 1,562.17). The movement in allowance for credit loss in respect of trade receivables during the year was as follows:

2.35 Financial instruments : Fair value and risk management (Contd..)

(iii) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company has an established liquidity risk management framework for managing its short term, medium term and long term funding and liquidity management requirements. The Company's exposure to liquidity risk arises primarily from mismatches of the maturities of financial assets and liabilities. The Company manages the liquidity risk by maintaining adequate funds in cash and cash equivalents. The Company also has adequate credit facilities agreed with banks to ensure that there is sufficient cash to meet all its normal operating commitments in a timely and cost-effective manner.

The Company uses a provision matrix to determine the expected credit loss on the portfolio of its trade receivables and contract assets. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and contract assets and is adjusted for forward looking estimates. The expected credit loss allowance is based on the ageing of the days the receivables are due in the provision matrix. Accordingly, the Company creates provision for past due receivables less than one year ranging between 2% to 25% and beyond one year ranging between 46% to 100%. Set out below is the information about the credit risk exposure of the Company’s trade receivables and contract asset using provision matrix:

The Company has secured loans from bank that contain loan covenants. A future breach of covenant may require the Company to repay the loan earlier than indicated in the above table.

C. Market risk

(i) Interest rate risk exposure

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company’s exposure to the risk of changes in market interest rates relates primarily to the Company’s long-term and short-term borrowings with variable interest rates.

Customer Concentration

No single customer represents 10% or more of the Company’s total revenue during the year ended 31 March 2024 and 31 March 2023. Therefore the customer concentration risk is limited due to the large and unrelated customer base.

Credit risk on cash and cash equivalent is limited as the Company generally transacts with banks and financial institutions with high credit ratings assigned by international and domestic credit rating agencies.

2.39 The Company did not have any long term contracts including derivative contracts for which there were any material foreseeable losses. The Company does not have any unhedged foreign currency exposure as at 31 March 2024 and 31 March 2023.

2.40 Other Statutory Information

(i) The Company do not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

(ii) The Company do not have any transactions with companies struck off.

(iii) The Company do not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.

Contract liability: During the financial year ended 31 March 2024, the Company has recognised revenue of Rs.126.93 from advance received from patients outstanding as on 31 March 2023. During the financial year ended 31 March 2023, the company has recognised revenue of Rs. 102.31 from advance received from patients outstanding as on 31 March 2022. It expects similarly to recognise revenue in year ended 31 March 2024 from the closing balance of advance from customers as at 31 March 2023.

Contract asset: During the financial year ended 31 March 2024, the company has transferred Rs. 98.38 of contract assets as at 31 March 2023 to trade receivables on completion of performance obligation. During the financial year ended 31 March 2023, the company has transferred Rs. 105.01 of contract assets as at 31 March 2022 to trade receivables on completion of performance obligation.

(iv) The Company have not traded or invested in Crypto currency or Virtual Currency during the financial year.

(v) The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

(vi) The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,

(vii) The Company do not have any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.

(viii) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.

(ix) The Company has not declared/paid any dividend during the year.

2.41 The Company has migrated to a new accounting software from legacy accounting software during the year on May 1,2023. The accounting softwares used for maintaining its books of account has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the softwares, except in respect of the new accounting software where audit trail feature is not enabled for certain changes made, if any, using privileged/administrative access rights to the new accounting application and the underlying Database. The Company is in the process of establishing necessary controls and documentations regarding audit trail in respect of the new accounting software. Further no instance of audit trail feature being tampered with was noted in respect of the accounting softwares used.

2.42 Events after the reporting period

There are no significant adjusting events that occurred subsequent to the reporting period.


 
KYC IS ONE TIME EXERCISE WHILE DEALING IN SECURITIES MARKETS - ONCE KYC IS DONE THROUGH A SEBI REGISTERED INTERMEDIARY (BROKER, DP, MUTUAL FUND ETC.), YOU NEED NOT UNDERGO THE SAME PROCESS AGAIN WHEN YOU APPROACH ANOTHER INTERMEDIARY. | PREVENT UNAUTHORISED TRANSACTIONS IN YOUR ACCOUNT --> UPDATE YOUR MOBILE NUMBERS/EMAIL IDS WITH YOUR STOCK BROKER/DEPOSITORY PARTICIPANT. RECEIVE INFORMATION/ALERT OF YOUR TRANSACTIONS DIRECTLY FROM EXCHANGE/NSDL ON YOUR MOBILE/EMAIL AT THE END OF THE DAY .......... ISSUED IN THE INTEREST OF INVESTORS
Disclaimer Clause | Privacy | Terms of Use | Rules and regulations | Feedback| IG Redressal Mechanism | Investor Charter | Client Bank Accounts
Right and Obligation, RDD, Guidance Note in Vernacular Language
Attention Investors : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
  "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
  "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participants. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL on the same day.Issued in the interest of Investors."
Regd. Office: 76-77, Scindia House, 1st Floor, Janpath, Connaught Place, New Delhi – 110001
NSE CASH , NSE F&O,NSE CDS| BSE CASH ,BSE CDS |DP NSDL | MCX-SX SEBI NO: INZ000155732

Compliance Officer: Mukesh Rustagi, Company Secretary, Tel: 011-46890000, Email: mukesh_rustagi80@hotmail.com
For grievances please e-mail at: kkslig@hotmail.com

Important Links : NSE | BSE | SEBI | NSDL | Speed-e | CDSL | SCORES | NSDL E-voting | CDSL E-voting
 
Charts are powered by TradingView.
Copyrights @ 2014 © KK Securities Limited. All Right Reserved
Designed, developed and content provided by